CoChat

High Resolution Discovery Proteomics Reveals Candidate Disease Progression Markers of Alzheimer’s Disease in Human Cerebrospinal Fluid

Open access
Hendrickson, Ronald C., Lee, Anita Y. H., Song, Qinghua, Liaw, Andy, Wiener, Matt, Paweletz, Cloud P., Seeburger, Jeffrey L., Li, Jenny, Meng, Fanyu, Deyanova, Ekaterina G., Mazur, Matthew T., Settlage, Robert E., Zhao, Xuemei, Southwick, Katie, Du, Yi, Holder, Dan, Sachs, Jeffrey R., Laterza, Omar F., Dallob, Aimee, Chappell, Derek L., Snyder, Karen, Modur, Vijay, King, Elizabeth, Joachim, Catharine, Bondarenko, Andrey Y., Shearman, Mark, Soper, Keith A., Smith, A. David, Potter, William Z., Koblan, Ken S., Sachs, Alan B., Yates, Nathan A. · 2015 · PLOS ONE
Cited by 69

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Disease modifying treatments for Alzheimer's disease (AD) constitute a major goal in medicine. Current trends suggest that biomarkers reflective of AD neuropathology and modifiable by treatment would provide supportive evidence for disease modification. Nevertheless, a lack of quantitative tools to assess disease modifying treatment effects remains a major hurdle. Cerebrospinal fluid (CSF) biochemical markers such as total tau, p-tau and Ab42 are well established markers of AD; however, global quantitative biochemical changes in CSF in AD disease progression remain largely uncharacterized. Here we applied a high resolution open discovery platform, dMS, to profile a cross-sectional cohort of lumbar CSF from post-mortem diagnosed AD patients versus those from non-AD/non-demented (control) patients. Multiple markers were identified to be statistically significant in the cohort tested. We selected two markers SME-1 (p<0.0001) and SME-2 (p = 0.0004) for evaluation in a second independent longitudinal cohort of human CSF from post-mortem diagnosed AD patients and age-matched and case-matched control patients. In cohort-2, SME-1, identified as neuronal secretory protein VGF, and SME-2, identified as neuronal pentraxin receptor-1 (NPTXR), in AD were 21% (p = 0.039) and 17% (p = 0.026) lower, at baseline, respectively, than in controls. Linear mixed model analysis in the longitudinal cohort estimate a decrease in the levels of VGF and NPTXR at the rate of 10.9% and 6.9% per year in the AD patients, whereas both markers increased in controls. Because these markers are detected by mass spectrometry without the need for antibody reagents, targeted MS based assays provide a clear translation path for evaluating selected AD disease-progression markers with high analytical precision in the clinic.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0135365

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 69

Metadata

Authors
Hendrickson, R. C., Lee, A. Y. H., Song, Q., Liaw, A., Wiener, M., Paweletz, C. P., Seeburger, J. L., Li, J., Meng, F., Deyanova, E. G., Mazur, M. T., Settlage, R. E., Zhao, X., Southwick, K., Du, Y., Holder, D., Sachs, J. R., Laterza, O. F., Dallob, A., Chappell, D. L., Snyder, K., Modur, V., King, E., Joachim, C., Bondarenko, A. Y., Shearman, M., Soper, K. A., Smith, A. D., Potter, W. Z., Koblan, K. S., Sachs, A. B., & Yates, N. A.
Venue
PLOS ONE
Published
2015-08-13
Volume
10
Issue
8
Pages
e0135365
ISSN
1932-6203 (ISSN-L)
OpenAlex
W1574604144
Cited by
69
References
9
FWCI
4.09
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.